4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazol-8-yl)benzonitrile for the treatment of positive symptoms of schizophrenia
Compound CF3CN treats positive symptoms of schizophrenia through different dosage forms and dosage forms, addressing the shortcomings of existing drug treatments and demonstrating significant efficacy in treating positive symptoms of schizophrenia.
CN122249211APending Publication Date: 2026-06-19ONTRACK THERAPEUTICS LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ONTRACK THERAPEUTICS LTD
- Filing Date
- 2024-11-22
- Publication Date
- 2026-06-19
AI Technical Summary
Technical Problem
Existing antipsychotic drugs have limited effectiveness in treating the positive symptoms of schizophrenia, and more effective treatment options are needed.
Method used
The compound 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydroxoneno[7,8-d]imidazol-8-yl)benzonitrile (CF3CN), administered in various dosage forms and doses, is used to treat positive symptoms of schizophrenia.
Benefits of technology
It significantly reduced positive symptoms of schizophrenia in animal models, such as spontaneous motor activity and hallucinations and delusions, providing a potential alternative to traditional antipsychotic drugs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122249211A_ABST
Abstract
This invention relates to compound 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromene[7,8-d]imidazol-8-yl)benzonitrile, also known as CF3CN, and referred herein as compound I, for use in the treatment of positive symptoms of schizophrenia.
Need to check novelty before this filing date? Find Prior Art